• UCLA Health
  • myUCLAhealth
  • School of Medicine
U Magazine

U Magazine

U Magazine
  • Home
  • Current Issue
  • Centennial Campaign for UCLA Issue
  • Browse U Magazine
  • Letters to the Editor
  • Subscribe
  • Contact
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

U Magazine

Browse U Magazine

  1. Home
  2. Browse U Magazine
Share this
The Cutting Edge

New Regulations Proposed for Off-label Drugs and Devices

  New Regulations Proposed for Off-label Drugs and Devices
 

Photo: Getty Images

The off-label use of drugs and medical devices — using approved remedies in unapproved ways — has long been a part of medicine, providing public-health benefits but also presenting some risks to patients. For the most part, the U.S. Food and Drug Administration (FDA) allows physicians to prescribe drugs and devices off-label in the same way they are prescribed for their approved uses, requiring healthcare providers to make their own decisions about using drugs off-label, often in the face of uncertain evidence.

Researchers from the David Geffen School of Medicine at UCLA and Yale University now have proposed a system combining reporting, testing and enforcement regulations and allowing interim periods of off-label drug prescriptions. Their recommendations would give patients more treatment options, while providing regulators with evidence of the drugs’ safety and efficacy.

Much off-label prescribing of medications and medical devices is beneficial, but without rigorous study, it is difficult to know what works and what doesn’t, says Ryan Abbott, MD, JD, visiting assistant professor of medicine. “Even though a drug or device has been approved for one indication, physicians can prescribe it for other uses as well; it’s been part of medical practice for a long time,” Dr. Abbott says. “Our proposals are important, because there is a tension between providing access to the drugs and devices that could benefit patients in untested ways and the need to prevent harmful uses.” The authors’ proposal is comprised of three elements:

• Improved reporting of off-label use through the disclosure of diagnostic codes in reports to the FDA, in detailing data that pharmaceutical companies obtain on physicians’ prescribing habits, and in reports to the FDA and Medicare/Medicaid reimbursement requests.

• Expansion of post-market testing requirements for off-label use of drugs and medical devices.

• A tiered labeling system for drugs consisting of “red-box” warnings that prohibit certain off-label uses; informed consent from patients receiving prescriptions for off-label use of some drugs that currently carry “black-box” warnings, which identify drugs that pose a significant risk of serious or life-threatening adverse effects; and the creation of a new “grey-box” warning that blocks Medicare Part D and Medicaid reimbursements by the Centers for Medicare and Medicaid Services.

“The improved reporting, testing and enforcement regulation would work together to produce a more layered range of regulatory responses,” the authors write. “The FDA, armed with better information about the extent of off-label use and adverse effects, would be in a better position to require post-market testing and to discourage off-label use with new types of warnings.”

“Evidence and Extrapolation: Mechanisms for Regulating Off-Label Uses of Drugs and Devices,” Duke Law Journal, December 2014


Previous
Antidepressant Exposure In Utero Influences Anxiety Behavior Later in Life
Next
Iron-overload Disease Causes Bloom of Potentially Deadly Bacteria


YOU ARE VIEWING

Spring 2015

Spring 2015
E-Brochure
Printable PDF
IN THIS ISSUE
  • Moving Forward
  • Bursting the Bubble of Bubble Baby Disease
  • Memories Lost and Found
  • Obesity Accelerates Aging of the Liver
  • ‘NanoVelcro’ Captures Tumor Cells in Blood
  • Robotic Surgery Technique Treats Previously Inoperable Head and Neck Cancer
  • Uncorking Targets for Acne Treatment
  • Antidepressant Exposure In Utero Influences Anxiety Behavior Later in Life
  • New Regulations Proposed for Off-label Drugs and Devices
  • Iron-overload Disease Causes Bloom of Potentially Deadly Bacteria
  • Helping U Help the Community: And the Winners Are ...
  • The Builder
  • Categorical Denial
  • What the Songbird Tells Us
  • Turning the Tables
  • Stress Fractures
  • Defining the Fairest Sex
  • Surfin' Safari
  • Awards/Honors
  • In His Own Words: Douglas J. Hopper, MD ’64 (RES ’68)
  • Reflection from an “Upstreamist” Doctor
  • Visions of Progress and Courage
  • Institute of Urologic Oncology Celebrates New Home
  • RX for Graceful Aging
  • New Kidney Transplant Center Enhances Patient Experience
  • Preparing Tomorrow’s Leaders
  • Chairs of Distinction
  • Gifts
  • In Memoriam
  • To Life!
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest

Sign in to myUCLAhealth